Hyperclinica MedLife Policlinica de Diagnostic Rapid Turnului Brasov
- Address
- lock Available on a paid plan
Hyperclinica MedLife Policlinica de Diagnostic Rapid Turnului Brasov
This advanced diagnostic and treatment facility specializes in oncology research with a particular focus on thoracic malignancies and precision medicine approaches. The center demonstrates expertise in conducting Phase 3 clinical trials for advanced non-small cell lung cancer (NSCLC), contributing to the development of innovative therapeutic strategies for patients with complex oncological conditions.
- Advanced Non-Small Cell Lung Cancer with KRAS G12C mutations
- Targeted molecular therapies for metastatic lung cancer
- Precision oncology and biomarker-driven treatment strategies
The facility's research portfolio emphasizes targeted therapeutic interventions for specific genetic mutations in lung cancer, particularly focusing on previously treated metastatic patients. Their participation in comparative efficacy studies positions them at the forefront of evaluating novel agents against standard chemotherapy regimens, supporting the advancement of personalized cancer treatment options for Romanian patients and the broader medical community.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hyperclinica MedLife Policlinica de Diagnostic Rapid Turnului Brasov
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Study of Adagrasib Versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation | Mirati Therapeutics Inc. | Phase III | Not Recruiting | Dec 2020 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adagrasib | 1 | Unknown | 2020-12-23 | 2020-12-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.